However, ERp57 exerts the opposite effect on gastric cancer progression; its expression is significantly decreased in gastric cancer and metastases, and low levels of ERp57 are correlated with an increased depth of tumor invasion and advanced disease stage 37. Here, PDIA3 is linked to gastric cancer.